Novel modalities and the regulatory pathways to clear their journey to patients are driving developments in rare disease treatments in 2025. In this episode of the Drug Solutions podcast, Patrick Lavery, editor for Pharmaceutical Technology®, Pharmaceutical Technology EuropeTM, and BioPharm International®, gathers perspectives from three key opinion leaders across the industry about advancements in oncology and other areas, and the increasing role of patients' families in accelerating R&D.

Sustainability has been a recent focus of both pharmaceutical companies and stakeholders. In this episode of the Drug Solutions podcast, Patrick Lavery, editor for Pharmaceutical Technology®, Pharmaceutical Technology EuropeTM, and BioPharm International®, gathers perspectives from five key opinion leaders across the industry about a variety of applications and equipment, and provides a look into how sustainable practices can be continued and improved upon in the years to come.

Adeno-associated virus (AAV) vectors have become widely used as delivery mechanisms in gene therapy, but there are some complex hurdles to be overcome. In this episode of the Drug Solutions podcast, Patrick Lavery, editor for Pharmaceutical Technology®, Pharmaceutical Technology EuropeTM, and BioPharm International®, surveys two attendees from the recent ASGCT conference about their approaches, the results they have achieved so far, and what further research or investigation might be needed to bring these therapeutic tweaks to a wider cross-section of patients.

In this episode of Drug Solutions, the discussion revolves around current and anticipated new trends in equipment and technologies for optimizing the manufacture of new biotherapeutic modalities, such as cell and gene therapies. Automation technologies and continuous manufacturing emerges as significant drivers for the future biomanufacturing landscape. Innovative and progressive technologies will also play a role in establishing and maintain sustainabililty practices in the industry.

In this episode of the Drug Solutions podcast, Felicity Thomas, Associate Editorial Director, chats with a host of experts about the trends that have impacted the bio/pharma industry in 2024 and those they expect to be impactful in 2025.

In this episode of the Drug Solutions podcast, Felicity Thomas, Associate Editorial Director, chats with a host of experts about artificial intelligence (AI) and the potential impact AI and machine learning may have on the global bio/pharma industry in the near future.

Dosage forms, in particular oral solid dose, continue to evolve as new technologies enter the market, and as customer tastes and demands change. In this episode of the Drug Solutions podcast, Patrick Lavery, editor for Pharmaceutical Technology®, Pharmaceutical Technology EuropeTM, and BioPharm International®, surveys attendees from the recent CPHI Milan gathering about how fast the market is expanding, how it's evolved in recent years and even decades, and what drugs are most conducive to OSD formulations.

The biopharmaceutical industry has long been working on methods to delivery biologic therapeutics in a manner that will enhance ease-of-use and patient compliance. Biologics today are largely administered parenterally, a method that can be painful and undesirable for patients. Furthermore, parenteral formulations of biologics require a strict temperature-controlled environment. Researchers have long been exploring means to formulate biologic-based molecules that can ensure their molecular stability and mitigate some of the stringent manufacturing requirements. In this episode of the Drug Solutions podcast, Feliza Mirasol, science editor of Pharmaceutical Technology®, Pharmaceutical Technology EuropeTM, and BioPharm International® explores the issues challenging biologic formulation and the progress made so far in moving toward alternative routes of biologic drug delivery with Nigel Theobald, CEO of N4 Pharma, a specialist pharmaceutical company developing novel delivery systems for oncology, gene therapy and vaccines.

In this sponsored episode, Jörg Zimmermann from Vetter chats about fill/finish advances.

In this episode of the Drug Solutions podcast, Felicity Thomas, Associate Editorial Director, chats with Hanns-Christian Mahler, CEO and board member of ten23 health, about the growing demand for fill/finish services, technological advances and novel approaches helping to advance fill/finish, sustainable and green practices, the impact of smaller batch sizes, and regulatory guidance updates in the space.

SPONSORS: Vetter